Is Volume Transfer Coefficient (K^trans) Related to Histologic Grade in Human Gliomas?

References

1. ↵
   Shin JH, Lee HK, Kwun BD, et al. Using relative cerebral blood flow and volume to evaluate the histopathologic grade of cerebral gliomas: preliminary results. AJR Am J Roentgenol 2002;179:783–789

   CrossRefPubMed
2. ↵
   Ludemann L, Grieger W, Wurm R, et al. Comparison of dynamic contrast-enhanced MRI with WHO tumor grading for gliomas. Eur Radiol 2001;11:1231–1241

   CrossRefPubMed
3. ↵
   Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 2003;24:1989–1998

   Abstract/FREE Full Text
4. ↵
   Law M, Cha S, Knopp EA, et al. High-grade gliomas and solitary metastases: differentiation by using perfusion and proton spectroscopic MR imaging. Radiology 2002;222:715–721

   PubMedWeb of Science
5. ↵
   Knopp EA, Cha S, Johnson G, et al. Glial neoplasms: dynamic contrast-enhanced T2*-weighted MR imaging. Radiology 1999;211:791–798

   CrossRefPubMedWeb of Science
6. ↵
   Fuss M, Wenz F, Essig M, et al. Tumor angiogenesis of low-grade astrocytomas measured by dynamic susceptibility contrast-enhanced MRI (DSC-MRI) is predictive of local tumor control after radiation therapy. Int J Radiat Oncol Biol Phys 2001;51:478–482

   CrossRefPubMed
7. ↵
   Aronen HJ, Perkio J. Dynamic susceptibility contrast MRI of gliomas. Neuroimaging Clin N Am 2002;12:501–523

   CrossRefPubMed
8. ↵
   Aronen HJ, Gazit IE, Louis DN, et al. Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology 1994;191:41–51

   PubMedWeb of Science
9. Haroon HA, Buckley DL, Patankar TA, et al. A comparison of Ktrans measurements obtained with conventional and first pass pharmacokinetic models in human gliomas. J Magn Reson Imaging 2004;19:527–536

   CrossRefPubMed
10. ↵
    Provenzale JM, Wang GR, Brenner T, et al. Comparison of permeability in high-grade and low-grade brain tumors using dynamic susceptibility contrast MR imaging. AJR Am J Roentgenol 2002;178:711–716

    CrossRefPubMedWeb of Science
11. ↵
    Roberts HC, Roberts TP, Brasch RC, Dillon WP. Quantitative measurement of microvascular permeability in human brain tumors achieved using dynamic contrast-enhanced MR imaging: correlation with histologic grade. AJNR Am J Neuroradiol 2000;21:891–899

    Abstract/FREE Full Text
12. ↵
    Sugahara T, Korogi Y, Kochi M, et al. Correlation of MR imaging-determined cerebral blood volume maps with histologic and angiographic determination of vascularity of gliomas. AJR Am J Roentgenol 1998;171:1479–1486

    CrossRefPubMedWeb of Science
13. ↵
    Croteau D, Scarpace L, Hearshen D, et al. Correlation between magnetic resonance spectroscopy imaging and image-guided biopsies: semiquantitative and qualitative histopathological analyses of patients with untreated glioma. Neurosurgery 2001;49:823–829

    CrossRefPubMedWeb of Science
14. ↵
    Wong ET, Jackson EF, Hess KR, et al. Correlation between dynamic MRI and outcome in patients with malignant gliomas. Neurology 1998;50:777–781

    Abstract/FREE Full Text
15. Wong JC, Provenzale JM, Petrella JR. Perfusion MR imaging of brain neoplasms. AJR Am J Roentgenol 2000;174:1147–1157

    PubMed
16. Cha S, Knopp EA, Johnson G, et al. Intracranial mass lesions: dynamic contrast-enhanced susceptibility-weighted echo-planar perfusion MR imaging. Radiology 2002;223:11–29

    CrossRefPubMedWeb of Science
17. Lev MH, Rosen BR. Clinical applications of intracranial perfusion MR imaging. Neuroimaging Clin N Am 1999;9:309–331

    PubMedWeb of Science
18. ↵
    Petrella JR, Provenzale JM. MR perfusion imaging of the brain: techniques and applications. AJR Am J Roentgenol 2000;175:207–219

    CrossRefPubMedWeb of Science
19. ↵
    Aronen HJ, Pardo FS, Kennedy DN, et al. High microvascular blood volume is associated with high glucose uptake and tumor angiogenesis in human gliomas. Clin Cancer Res 2000;6:2189–2200

    Abstract/FREE Full Text
20. ↵
    Lev MH, Ozsunar Y, Henson JW, et al. Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. AJNR Am J Neuroradiol 2004;25:214–221

    Abstract/FREE Full Text
21. ↵
    Tofts PS, Brix G, Buckley DL, et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)- weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999;10:223–232

    CrossRefPubMedWeb of Science
22. ↵
    Li KL, Zhu XP, Checkley DR, et al. Simultaneous mapping of blood volume and endothelial permeability surface area product in gliomas using iterative analysis of first-pass dynamic contrast enhanced MRI data. Br J Radiol 2003;76:39–50

    Abstract/FREE Full Text
23. ↵
    Zhu XP, Li KL, Kamaly-Asl ID, et al. Quantification of endothelial permeability, leakage space, and blood volume in brain tumors using combined T₁ and T2* contrast-enhanced dynamic MR imaging. J Magn Reson Imaging 2000;11:575–585

    CrossRefPubMedWeb of Science
24. Johnson G, Wetzel SG, Cha S, et al. Measuring blood volume and vascular transfer constant from dynamic, T(2)*-weighted contrast-enhanced MRI. Magn Reson Med 2004;51:961–968

    CrossRefPubMed
25. ↵
    Weisskoff R, Boxermann J, Sorensen A, et al. Simultaneous blood volume and permeability mapping using a single Gd-based contrast injection. In: Proceedings of the International Society of Magnetic Resonance in Medicine. ISMRM: Berkeley, CA;1994 :279
26. ↵
    Nasel C, Schindler E. [Xenon-CT and perfusion MRI in the diagnosis of cerebral gliomas]. Radiologe 1998;38:930–934

    PubMed
27. ↵
    Nakagawa T, Tanaka R, Takeuchi S, Takeda N. Haemodynamic evaluation of cerebral gliomas using XeCT. Acta Neurochir (Wien) 1998;140:223–233; discussion 233–224

    CrossRefPubMedWeb of Science
28. ↵
    van Dijke CF, Brasch RC, Roberts TP, et al. Mammary carcinoma model: correlation of macromolecular contrast-enhanced MR imaging characterizations of tumor microvasculature and histologic capillary density. Radiology 1996;198:813–818

    PubMedWeb of Science
29. Schwickert HC, Stiskal M, Roberts TP, et al. Contrast-enhanced MR imaging assessment of tumor capillary permeability: effect of irradiation on delivery of chemotherapy. Radiology 1996;198:893–898

    PubMed
30. ↵
    Dvorak HF, Detmar M, Claffey KP, et al. Vascular permeability factor/vascular endothelial growth factor: an important mediator of angiogenesis in malignancy and inflammation. Int Arch Allergy Immunol 1995;107:233–235

    CrossRefPubMedWeb of Science
31. ↵
    Law M, Yang S, Babb JS, et al. Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. AJNR Am J Neuroradiol 2004;25:746–755

    Abstract/FREE Full Text
32. ↵
    Kleihues P, Louis DN, Scheithauer BW, et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002;61:215–225; discussion 226–229

    PubMedWeb of Science
33. ↵
    Li KL, Zhu XP, Waterton J, Jackson A. Improved 3D quantitative mapping of blood volume and endothelial permeability in brain tumors. J Magn Reson Imaging 2000;12:347–357

    CrossRefPubMed
34. ↵
    Tabachnick B, Fidell L. Using multivariate statistics. New York: Harper Collins;1996
35. ↵
    Li KL, Jackson A. New hybrid technique for accurate and reproducible quantitation of dynamic contrast-enhanced MRI data. Magn Reson Med 2003;50:1286–1295

    CrossRefPubMed
36. ↵
    Jackson A, Kassner A, Annesley-Williams D, et al. Abnormalities in the recirculation phase of contrast agent bolus passage in cerebral gliomas: comparison with relative blood volume and tumor grade. AJNR Am J Neuroradiol 2002;23:7–14

    Abstract/FREE Full Text
37. ↵
    Sugahara T, Korogi Y, Kochi M, et al. Perfusion-sensitive MR imaging of gliomas: comparison between gradient-echo and spin-echo echo-planar imaging techniques. AJNR Am J Neuroradiol 2001;22:1306–1315

    Abstract/FREE Full Text
38. ↵
    Roberts TP. Physiologic measurements by contrast-enhanced MR imaging: expectations and limitations. J Magn Reson Imaging 1997;7:82–90

    PubMedWeb of Science
39. ↵
    Jackson A, Jayson GC, Li KL, et al. Reproducibility of quantitative dynamic contrast-enhanced MRI in newly presenting glioma. Br J Radiol 2003;76:153–162

    Abstract/FREE Full Text
40. ↵
    Ludemann L, Hamm B, Zimmer C. Pharmacokinetic analysis of glioma compartments with dynamic Gd-DTPA-enhanced magnetic resonance imaging. Magn Reson Imaging 2000;18:1201–1214

    CrossRefPubMed
41. ↵
    Kassner A, Annesley DJ, Zhu XP, et al. Abnormalities of the contrast re-circulation phase in cerebral tumors demonstrated using dynamic susceptibility contrast-enhanced imaging: a possible marker of vascular tortuosity. J Magn Reson Imaging 2000;11:103–113

    CrossRefPubMed
42. ↵
    Jackson A, Kassner A, Zhu XP, Li KL. Reproducibility of T2* blood volume and vascular tortuosity maps in cerebral gliomas. J Magn Reson Imaging 2001;14:510–516

    CrossRefPubMed
43. Bruening R, Kwong KK, Vevea MJ, et al. Echo-planar MR determination of relative cerebral blood volume in human brain tumors: T1 versus T2 weighting. AJNR Am J Neuroradiol 1996;17:831–840

    Abstract
44. ↵
    Hacklander T, Hofer M, Reichenbach JR, et al. Cerebral blood volume maps with dynamic contrast-enhanced T1-weighted FLASH imaging: normal values and preliminary clinical results. J Comput Assist Tomogr 1996;20:532–539

    CrossRefPubMed
45. ↵
    Jackson A, Haroon H, Zhu XP, et al. Breath-hold perfusion and permeability mapping of hepatic malignancies using magnetic resonance imaging and a first-pass leakage profile model. NMR Biomed 2002;15:164–173

    CrossRefPubMedWeb of Science